Phase I/IIa trials of a novel T-cell epitope-based peptide therapy for peanut allergy [ 2016 - ]

Research Grant

Researchers: Prof Robyn O'Hehir (Principal investigator)

Brief description Peanut allergy affects ~2% of the population and is the major cause of food triggered deaths from anaphylaxis. Typically peanut allergy is lifelong. Currently there is no specific treatment. Our vast experience in immunology for house dust mite and grass immunotherapy allowed us to identify critical components of peanut proteins needed as a safe vaccine to build tolerance to peanut foods. Now we will progress this novel and revolutionary vaccine through early phase clinical trials.

Funding Amount $1,440,000.00

Funding Scheme Project Grants

Notes Standard Project Grant